Neuromyelitis Optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue.
In the disease process of NMO, for reasons that aren’t yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Market Segment as follows:
Middle East & Africa.
Production Market Share
Remission prophylactic treatment.
Go to sample Report@https://www.reportsandmarkets.com/sample-request/global-and-regional-neuromyelitis-optica-drug-market-research-report-2017-1651929
The main contents of the report including:
Product definition, type and application, global and regional market overview;
Global and regional Market competition by company;
Global and regional sales revenue, volume and price by type;
Global and regional sales revenue, volume and price by application;
Regional export and import;
Company information, business overview, sales data and product specifications;
Industry chain and raw materials;
SWOT and Porter’s Five Forces;
Get Discount on Report purchasing@https://www.reportsandmarkets.com/check-discount/global-and-regional-neuromyelitis-optica-drug-market-research-report-2017-1651929